Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Anthony S Prokopowicz, Iii

Frank Himmelsbach

Georg Dahmann

Alexander Pautsch

Martin Steegmaier

Denice Mary Spero

Mario G Cardozo

Derek Cogan

Charles Lawrence Cywin

Erick Richard Roush Young

Steffen Steurer

Walter Spevak

Andreas Schoop

John David Ginn

Martin Lenter

Gisela Schnapp

Darren DiSalvo

Bernd Krist

Helmut Wittneben

George Dahmann

Disclosed are novel compounds of formula (I): wherein R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

The present invention relates to trisubstituted pyrimidines of formula (I) wherein0Rto Rare defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

Pyrimidine derivatives

Growing community of inventors

Beekman, NY, United States of America

Anthony S Prokopowicz, Iii